NYSE$AMPE
Ampio Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Ampio Pharmaceuticals reported financial results for Q3 2021 and provided a business update.
Ampio Pharmaceuticals reported cash and cash equivalents of $17.1 million. They also reported a net loss of $3.628 million, or $0.02 per share.
- Cash and cash equivalents totaled $17.1 million as of September 30, 2021.
- The osteoarthritis Phase 3 pivotal trial database has been locked and data is being analyzed.
- Enrollment and treatment of COVID-19 patients in India has commenced for the Phase 2 AP-019 study.
- Ampio continues to investigate Ampion’s potential in new indications within the preclinical space.
Headline financials
Revenue & EPS history
Ampio · Revenue · Quarterly
$0
Forward guidance
Ampio expects to have cash and cash equivalents along with access to external sources of liquidity sufficient to fund its business operations through the first quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.4%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-17.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+32.5%
Q1 2011
Best reaction
-20.0%
Q4 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +13.4% | -2.2% | -60.4% | |
| Q3 2023 | +6.2% | +0.1% | -21.1% | |
| Q2 2023 | +4.8% | -0.3% | +3.0% | |
| Q1 2023 | -8.3% | -8.9% | -3.5% | |
| Q4 2022 | +4.0% | -6.8% | -16.9% | |
| Q3 2022 | -18.9% | +8.1% | -25.8% | |
| Q3 2024 | -10.3% | -31.0% | -46.0% | |
| Q2 2022 | -9.1% | -4.5% | -15.9% | |
| Q1 2022 | +0.0% | -1.7% | -50.0% | |
| Q4 2021 | -8.0% | -7.7% | -57.2% | |
| Q3 2021 | -14.7% | -19.6% | -39.2% | |
| Q2 2021 | +9.8% | +13.6% | +28.8% | |
| Q1 2021 | +12.8% | +7.9% | -99.6% | |
| Q4 2020 | -5.5% | -10.9% | +12.1% | |
| Q3 2020 | +1.2% | -6.4% | +27.4% | |
| Q2 2020 | -1.9% | +0.9% | -30.4% | |
| Q1 2020 | +23.3% | +14.6% | +42.9% | |
| Q3 2019 | -7.7% | -7.3% | +7.1% | |
| Q1 2019 | +0.0% | -5.8% | +1.4% | |
| Q4 2018 | -8.8% | -16.2% | -24.7% | |
| Q3 2018 | -1.7% | -1.5% | -31.5% | |
| Q2 2018 | -2.1% | +0.6% | +26.3% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -4.9% | — | — | |
| Q2 2011 | -1.3% | — | — | |
| Q1 2011 | +32.5% | — | — | |
| Q4 2010 | -20.0% | — | — | |
| Q3 2010 | -3.3% | — | — | |
| Q2 2010 | +27.3% | — | — | |
| Q1 2010 | -14.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro